• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Veracyte Inc.

    6/17/25 4:37:36 PM ET
    $VCYT
    Medical Specialities
    Health Care
    Get the next $VCYT alert in real time by email
    S-8 1 vcyt-06172025xs8.htm S-8 Document

    As filed with the Securities and Exchange Commission on June 17, 2025
    Registration No. 333-
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    ____________________
    FORM S-8
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933
    ____________________
    VERACYTE, INC.
    (Exact name of registrant as specified in its charter)
    Delaware
    (State or other jurisdiction of
    incorporation or organization)
    20-5455398
     (I.R.S. Employer
    Identification No.)
    6000 Shoreline Court, Suite 300
    South San Francisco, California
    (Address of Principal Executive Offices)
    94080
    (Zip Code)
    Veracyte, Inc. 2023 Equity Incentive Plan
    (Full title of the plan)
    Marc Stapley
    Chief Executive Officer
    6000 Shoreline Court, Suite 300
    South San Francisco, California
    (Name and address of agent for service)
    (650) 243-6300
    (Telephone number, including area code, of agent for service)
    Copies to:

    Jim Krenn, Esq.
    Morrison & Foerster LLP
    12531 High Bluff Drive
    San Diego, CA 92130
    (858) 720-5100

    Emily Beers, Esq.
    Morrison & Foerster LLP
    2100 L Street NW, Suite 900
    Washington, D.C. 20037
    (202) 887-1500
    Annie McGuire Esq.
    Executive Vice President and
    General Counsel
    Veracyte, Inc.
    6000 Shoreline Court, Suite 300
    South San Francisco, CA 94080
    (650) 243-6300

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
    Large accelerated filer☒Accelerated filer☐
    Non-accelerated filer☐Smaller reporting company☐
    Emerging growth company☐





    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐






    REGISTRATION OF ADDITIONAL SHARES PURSUANT TO GENERAL INSTRUCTION E

    Pursuant to General Instruction E of Form S-8, Veracyte, Inc. (the “Registrant”) is filing this Registration Statement on Form S-8 with the U.S. Securities and Exchange Commission (the “Commission”) to register 2,500,000 additional shares (the “Share Increase”) of the Registrant’s common stock, par value $0.001 per share (the “common stock”), available for issuance under the Registrant’s 2023 Equity Incentive Plan, as amended (the “2023 Plan”). At the Registrant’s Annual Meeting of Stockholders held on June 17, 2025, the Registrant’s stockholders, among other things, approved the Share Increase under the 2023 Plan.

    In accordance with General Instruction E of Form S-8, and only with respect to the common stock issuable under the 2023 Plan, this Registration Statement hereby incorporates by reference the contents of (i) the Registrant’s Registration Statements on Form S-8 filed with the Commission on October 30, 2013 (File No. 333-191992), March 30, 2015 (File No. 333-203097), March 14, 2016 (File No. 333-210185), March 2, 2017 (File No. 333-216388), February 28, 2018 (File No. 333-223292), February 25, 2019 (File No. 333-229848), February 25, 2020 (File No. 333-236630), February 22, 2021 (File No. 333-253363), March 1, 2022 (File No. 333-263116), March 1, 2023 (File No. 333-270147), in each case as amended by a Post-Effective Amendment No. 1 thereto filed with the Commission on June 8, 2023, and (ii) the Registrant’s Registration Statement on Form S-8 filed with the Commission on June 12, 2024 (File No. 333-280150), in each case, to the extent not superseded hereby.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference.
    The following documents filed by the Registrant with the Commission are hereby incorporated by reference in this Registration Statement:
    (a)    The Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Commission on February 28, 2025;
    (b)    All other reports filed pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") since the end of the fiscal year covered by the Registrant’s Annual Report referred to in (a) above (other than the portions of these documents not deemed to be filed); and
    (c)    The description of the Registrant’s common stock contained in Registrant’s registration statement on Form 8-A, filed with the Commission on October 28, 2013 pursuant to Section 12(b) of the Exchange Act, including any amendment or report filed for the purpose of updating such description, including Exhibit 4.2 to the Registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on February 28, 2025.

    In addition, all documents filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act (excluding any portions thereof furnished by the Registrant, including information furnished under Item 2.02 and Item 7.01 and any exhibits relating to Item 2.02 or Item 7.01 furnished under Item 9.01 of Form 8-K and any certification required by 18 U.S.C. § 1350), subsequent to the filing of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing such documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement.





    Item 8.Exhibits.
    The following exhibits are filed herewith:

    Incorporated by Reference
    Exhibit No.DescriptionFormFile No.ExhibitFiling DateFiled Herewith
    4.1
    Restated Certificate of Incorporation of the Registrant
    8-K001-361563.26/9/2023
    4.2
    Amended and Restated Bylaws of the Registrant
    8-K001-361563.36/9/2023
    4.3
    Form of Common Stock Certificate
    S-1/A333-1912824.110/15/2013
    5.1
    Opinion of Morrison & Foerster LLP
    X
    23.1
    Consent of Independent Registered Public Accounting Firm
    X
    23.2
    Consent of Morrison & Foerster LLP (included in Exhibit 5.1)
    X
    24.1
    Power of Attorney (contained on signature page hereto).
    X
    99.1
    2023 Equity Incentive Plan, as amended
    DEF 14-A001-36156Appendix A4/29/2025
    99.2
    Form of agreements under the 2023 Equity Incentive Plan
    S-8 POS333-27014799.66/8/2023
    107.1
    Filing Fee Table
    X







    SIGNATURES
    Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized in the City of South San Francisco, State of California, on the 17th day of June 2025.
    VERACYTE, INC.
    By:/s/ MARC STAPLEY
    Marc Stapley
    Chief Executive Officer and Director






    POWER OF ATTORNEY

    KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Marc Stapley and Rebecca Chambers and each of them, his or her true and lawful attorneys-in-fact and agents, each with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments, including post-effective amendments, to this Registration Statement on Form S-8, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that each of said attorneys-in-fact and agents, or his or her substitute or substitutes may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

    SignatureTitleDate
    /s/ MARC STAPLEYChief Executive Officer and Director
    (Principal Executive Officer)
    June 17, 2025
    Marc Stapley
    /s/ REBECCA CHAMBERSChief Financial Officer
    (Principal Financial Officer)
    June 17, 2025
    Rebecca Chambers
    /s/ JONATHAN WYGANTChief Accounting Officer (Principal Accounting Officer)June 17, 2025
    Jonathan Wygant
    /s/ ROBERT S. EPSTEIN, M.D., M.S.Chairperson and DirectorJune 17, 2025
    Robert S. Epstein, M.D., M.S.
    /s/ ELIAV BARR, M.D.DirectorJune 17, 2025
    Eliav Barr, M.D.
    /s/ MUNA BHANJIDirectorJune 17, 2025
    Muna Bhanji
    /s/ KARIN EASTHAMDirectorJune 17, 2025
    Karin Eastham
    /s/ JENS HOLSTEINDirectorJune 17, 2025
    Jens Holstein
    /s/ EVAN JONESDirectorJune 17, 2025
    Evan Jones
    /s/ TOM MILLERDirectorJune 17, 2025
    Tom Miller
    /s/ BRENT SHAFERDirectorJune 17, 2025
    Brent Shafer


    Get the next $VCYT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VCYT

    DatePrice TargetRatingAnalyst
    3/20/2025$45.00Buy
    Craig Hallum
    12/5/2024$38.00 → $37.00Buy → Neutral
    Goldman
    11/15/2024$50.00Outperform
    Wolfe Research
    10/16/2024$43.00Buy
    UBS
    10/10/2024$40.00Buy
    Guggenheim
    2/23/2024$30.00 → $33.00Buy
    Needham
    1/18/2023Outperform → Mkt Perform
    Raymond James
    1/5/2023$33.00Sector Outperform
    Scotiabank
    More analyst ratings